Routine pre-operative imaging of the primary tumour and axillary lymph nodes in breast cancer helps determine treatment decisions in individual patients. MRF imaging of the primary tumour could have a major impact in better delineation of the primary tumour in the breast to facilitate more accurate resection. If MRF proves to be a biomarker signature that can predict for positive lymph node involvement, it will also allow for more accurate staging of the axillary lymph nodal basin pre-operatively and may eliminate the need to perform sentinel lymph node biopsy in the future. Furthermore, MRF as an imaging biomarker that is indicative of metastatic potential could help guide treatment decisions with regard to neoadjuvant systemic therapy. Non-invasive IFP measurements by MRF in patients undergoing neoadjuvant systemic therapy would enable the monitoring of patients’ response whilst on therapy. This could help guide decisions with regard to switching treatment early in those patients who show resistance to particular therapeutic regimens, (non-responders), thereby minimizing unnecessary toxicity and facilitating better therapeutic response.